GRO Biosciences, an innovative biotechnology company, is transforming the landscape of protein therapeutics by expanding the amino acid alphabet. Based in Cambridge, Massachusetts, GRO is dedicated to addressing unmet clinical needs through its proprietary GRO platform, which facilitates the development of non-standard amino acid (NSAA) proteins. These advanced therapeutics have the potential to greatly enhance the potency, stability, and overall functionality of protein-based treatments.

With a strong focus on autoimmune diseases and metabolic disorders, GRO is pioneering two main families of NSAA chemistries: DuraLogic™ and ProGly™. DuraLogic™ is designed for improved therapeutic stability and dosing schedules, while ProGly™ aims to reeducate the immune system, minimizing the side effects commonly associated with traditional protein therapies.

Backed by substantial funding and strategic partnerships, including collaboration with Leaps by Bayer, GRO Biosciences is committed to delivering the next generation of therapies that redefine how complex diseases are treated, ultimately improving patient outcomes.